Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz SA, Rogers KA, Byrd JC, Woyach JA, Blachly JS. Lucas F, et al. Among authors: ngankeu a. Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722. Blood. 2020. PMID: 32232486 Free PMC article. No abstract available.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR. Rogers KA, et al. Among authors: ngankeu a. Blood. 2021 Jun 24;137(25):3473-3483. doi: 10.1182/blood.2020009688. Blood. 2021. PMID: 33754642 Free PMC article. Clinical Trial.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS. Saygin C, et al. Among authors: ngankeu a. Am J Hematol. 2020 Dec;95(12):1457-1465. doi: 10.1002/ajh.25958. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32777116 Free PMC article. Clinical Trial.
Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.
Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. Gaudio E, et al. Among authors: ngankeu a. Blood. 2013 Jan 10;121(2):351-9. doi: 10.1182/blood-2012-09-457374. Epub 2012 Nov 15. Blood. 2013. PMID: 23160471 Free PMC article.
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. Garofalo M, et al. Among authors: ngankeu a. Nat Med. 2011 Dec 11;18(1):74-82. doi: 10.1038/nm.2577. Nat Med. 2011. PMID: 22157681 Free PMC article. Retracted.
Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD).
Efebera YA, Ruppert AS, Ngankeu A, Garman S, Kumchala P, Howard A, Devine SM, Ranganathan P, Garzon R. Efebera YA, et al. Among authors: ngankeu a. Int J Bone Marrow Res. 2019;2:079-82. doi: 10.29328/journal.ijbmr.1001007. Epub 2019 Aug 16. Int J Bone Marrow Res. 2019. PMID: 34079960 Free PMC article. No abstract available.
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.
Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan RI, Croce CM, Bertoni F, Alcaro S, Trapasso F. Gaudio E, et al. Among authors: ngankeu a. Br J Haematol. 2018 Nov;183(3):509-512. doi: 10.1111/bjh.14989. Epub 2017 Oct 19. Br J Haematol. 2018. PMID: 29048125 Free article. No abstract available.
21 results